Mylan Slumps in After-Hours Trading on Generic Advair Update
Down goes Mylan.

Pounded. 

Mylan NV (MYL) said Wednesday, June 13, that the U.S. Food and Drug Administration "has identified minor deficiencies" that the agency will relay in a letter later this month regarding Mylan's application for a generic version of  GlaxoSmithKline plc's (GSK) asthma drug Advair.

The FDA will issue a complete response letter, which indicates that an application is not yet ready for approval, on June 27.

Shares of Mylan fell 4.3% to $39.90 in after-hours trading. GlaxoSmithKline's American Depository Receipts were up 2.5% to $42.15.

"Because our Abbreviated New Drug Application has received a priority designation, our approval could be received prior to the standard 90-day time period following the date of our response to the Complete Response Letter," Mylan said.

More from Markets

U.S. Stocks Set For Solid Open as Q3 Earnings Impress; Goldman Boosts Dow

U.S. Stocks Set For Solid Open as Q3 Earnings Impress; Goldman Boosts Dow

Goldman Sachs Profit Jumps as Tax Cuts Fatten the Bottom Line

Goldman Sachs Profit Jumps as Tax Cuts Fatten the Bottom Line

IBM Reports Earnings on Tuesday: 7 Key Things to Watch

IBM Reports Earnings on Tuesday: 7 Key Things to Watch

Netflix, Goldman Sachs, Paul Allen, Google and Ford - 5 Things You Must Know

Netflix, Goldman Sachs, Paul Allen, Google and Ford - 5 Things You Must Know

Walmart Trims 2019 Earnings Guidance After $16 Billion Flipkart Deal

Walmart Trims 2019 Earnings Guidance After $16 Billion Flipkart Deal